Financhill
Sell
40

DBVT Quote, Financials, Valuation and Earnings

Last price:
$9.86
Seasonality move :
9.38%
Day range:
$9.35 - $9.86
52-week range:
$2.20 - $9.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
90.45x
Volume:
93.9K
Avg. volume:
840.6K
1-year change:
39.71%
Market cap:
$259.8M
Revenue:
--
EPS (TTM):
-$5.70

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.95% $15.52
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -92.5% -8.33% $1.71
ASND
Ascendis Pharma AS
$107.9M -$1.71 294.94% -25.18% $222.60
CLLS
Cellectis SA
$13.8M -- 204.72% -100% $5.80
EDAP
Edap TMS SA
$16.6M -$0.17 1.37% -27.74% $8.50
GNFT
Genfit SA
$151.2M -- -- -- $10.17
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DBVT
DBV Technologies SA
$9.50 $15.52 $259.8M -- $0.00 0% --
ADAP
Adaptimmune Therapeutics PLC
$0.30 $1.71 $77.2M -- $0.00 0% 0.43x
ASND
Ascendis Pharma AS
$160.99 $222.60 $9.7B -- $0.00 0% 23.98x
CLLS
Cellectis SA
$1.53 $5.80 $152.6M -- $0.00 0% 3.61x
EDAP
Edap TMS SA
$2.30 $8.50 $86M -- $0.00 0% 1.24x
GNFT
Genfit SA
$4.25 $10.17 $212.5M 32.57x $0.00 0% 2.95x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DBVT
DBV Technologies SA
-- -3.919 -- --
ADAP
Adaptimmune Therapeutics PLC
80.92% 3.631 36.44% 2.60x
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
CLLS
Cellectis SA
27.15% 0.907 37.63% 1.70x
EDAP
Edap TMS SA
20.91% -0.651 13.72% 1.33x
GNFT
Genfit SA
-- 0.519 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
ADAP
Adaptimmune Therapeutics PLC
-- -$57.2M -93.9% -140.5% -2197.67% -$35.4M
ASND
Ascendis Pharma AS
$87.8M -$109.7M -59.13% -880.05% -48.32% -$90.9M
CLLS
Cellectis SA
-- -$10.7M -22.9% -31.46% 65.62% -$1.8M
EDAP
Edap TMS SA
$9.7M -$4M -35.42% -39.5% -8.35% $246.1K
GNFT
Genfit SA
-- -- -- -- -- --

DBV Technologies SA vs. Competitors

  • Which has Higher Returns DBVT or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -- compared to DBV Technologies SA's net margin of -2303.38%. DBV Technologies SA's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    DBVT
    DBV Technologies SA
    -- -$1.30 --
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.31 $62.1M
  • What do Analysts Say About DBVT or ADAP?

    DBV Technologies SA has a consensus price target of $15.52, signalling upside risk potential of 63.35%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 468.75%. Given that Adaptimmune Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Adaptimmune Therapeutics PLC is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    DBVT
    DBV Technologies SA
    0 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    2 3 0
  • Is DBVT or ADAP More Risky?

    DBV Technologies SA has a beta of -0.661, which suggesting that the stock is 166.125% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.

  • Which is a Better Dividend Stock DBVT or ADAP?

    DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DBVT or ADAP?

    DBV Technologies SA quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. DBV Technologies SA's net income of -$27.1M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.43x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
    ADAP
    Adaptimmune Therapeutics PLC
    0.43x -- $3.2M -$74.2M
  • Which has Higher Returns DBVT or ASND?

    Ascendis Pharma AS has a net margin of -- compared to DBV Technologies SA's net margin of -93.73%. DBV Technologies SA's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    DBVT
    DBV Technologies SA
    -- -$1.30 --
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About DBVT or ASND?

    DBV Technologies SA has a consensus price target of $15.52, signalling upside risk potential of 63.35%. On the other hand Ascendis Pharma AS has an analysts' consensus of $222.60 which suggests that it could grow by 38.27%. Given that DBV Technologies SA has higher upside potential than Ascendis Pharma AS, analysts believe DBV Technologies SA is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    DBVT
    DBV Technologies SA
    0 0 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is DBVT or ASND More Risky?

    DBV Technologies SA has a beta of -0.661, which suggesting that the stock is 166.125% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock DBVT or ASND?

    DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DBVT or ASND?

    DBV Technologies SA quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. DBV Technologies SA's net income of -$27.1M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 23.98x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
    ASND
    Ascendis Pharma AS
    23.98x -- $106.2M -$99.6M
  • Which has Higher Returns DBVT or CLLS?

    Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of 46.57%. DBV Technologies SA's return on equity of -- beat Cellectis SA's return on equity of -31.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    DBVT
    DBV Technologies SA
    -- -$1.30 --
    CLLS
    Cellectis SA
    -- $0.08 $179.9M
  • What do Analysts Say About DBVT or CLLS?

    DBV Technologies SA has a consensus price target of $15.52, signalling upside risk potential of 63.35%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 280.33%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    DBVT
    DBV Technologies SA
    0 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is DBVT or CLLS More Risky?

    DBV Technologies SA has a beta of -0.661, which suggesting that the stock is 166.125% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock DBVT or CLLS?

    DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DBVT or CLLS?

    DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $12.7M. DBV Technologies SA's net income of -$27.1M is lower than Cellectis SA's net income of $5.9M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 3.61x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
    CLLS
    Cellectis SA
    3.61x -- $12.7M $5.9M
  • Which has Higher Returns DBVT or EDAP?

    Edap TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -9.55%. DBV Technologies SA's return on equity of -- beat Edap TMS SA's return on equity of -39.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    DBVT
    DBV Technologies SA
    -- -$1.30 --
    EDAP
    Edap TMS SA
    44.78% -$0.05 $53.8M
  • What do Analysts Say About DBVT or EDAP?

    DBV Technologies SA has a consensus price target of $15.52, signalling upside risk potential of 63.35%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 269.57%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    DBVT
    DBV Technologies SA
    0 0 0
    EDAP
    Edap TMS SA
    0 1 0
  • Is DBVT or EDAP More Risky?

    DBV Technologies SA has a beta of -0.661, which suggesting that the stock is 166.125% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.225%.

  • Which is a Better Dividend Stock DBVT or EDAP?

    DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DBVT or EDAP?

    DBV Technologies SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $21.7M. DBV Technologies SA's net income of -$27.1M is lower than Edap TMS SA's net income of -$2.1M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 1.24x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
    EDAP
    Edap TMS SA
    1.24x -- $21.7M -$2.1M
  • Which has Higher Returns DBVT or GNFT?

    Genfit SA has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DBVT
    DBV Technologies SA
    -- -$1.30 --
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About DBVT or GNFT?

    DBV Technologies SA has a consensus price target of $15.52, signalling upside risk potential of 63.35%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 147.78%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    DBVT
    DBV Technologies SA
    0 0 0
    GNFT
    Genfit SA
    1 0 0
  • Is DBVT or GNFT More Risky?

    DBV Technologies SA has a beta of -0.661, which suggesting that the stock is 166.125% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

  • Which is a Better Dividend Stock DBVT or GNFT?

    DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DBVT or GNFT?

    DBV Technologies SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. DBV Technologies SA's net income of -$27.1M is higher than Genfit SA's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 2.95x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
    GNFT
    Genfit SA
    2.95x 32.57x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 6.67% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock